Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Rifabutin

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The clinical effectiveness of rifabutin for prophylaxis of disseminated Mycobacterium avium complex infection has recently been demonstrated in HIV-positive patients with low CD4 counts. Rifabutin is a newly marketed, semisynthetic antimycobacterial agent similar to rifampicin (rifampin) in structure and activity. However, rifabutin has important pharmacokinetic differences compared with rifampicin.

Rifabutin has relatively low oral bioavailability; about 20% after single dose administration. With long term administration rifabutin induces its own metabolism and the metabolism of some other drugs. The elimination half-life of rifabutin is long (45 hours) but, as a result of a very large volume of distribution (>9 L/kg), average plasma concentrations remain relatively low after repeated administration of standard doses.

In vitro rifabutin is more active against M. avium-intracellulare complex and at least as active against M. tuberculosis as rifampicin. In vivo the advantage of rifabutin is less apparent due to its lower plasma concentrations at equivalent doses. Adverse effects are unusual at the recommended oral dosage of 300 mg/day, but become common as the total daily dose approaches 1g. Dose-limiting toxicity consists of a polyarthralgia/arthritis syndrome, possibly complicated by uveitis. More clinical studies are needed to establish the role of rifabutin in combination therapy for M. avium-intracellulare complex and other mycobacterial infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marsili L, Pasqualucci CR, Vigevani A, et al. New rifamycins modified at positions 3 and 4: synthesis, structure and biological evaluations. J Antibiot (Tokyo) 1981; 34: 1033–8

    Article  CAS  Google Scholar 

  2. Biagi GL, Barbaro AM, Gamba MF, et al. Partition data of penicillins determined by means of reversed-phase thin layer chromatography. J Chromatogr 1969; 41: 371–9

    PubMed  CAS  Google Scholar 

  3. Battaglia R, Pianezzola E, Salgarollo G, et al. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. J Antimicrob Chemother 1990; 26: 813–22

    Article  PubMed  CAS  Google Scholar 

  4. Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res 1991; 8: 1434–40

    Article  PubMed  CAS  Google Scholar 

  5. Van der Auwera P, Scorneaux B. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother 1985; 28: 440–1

    Article  Google Scholar 

  6. Woodley CL, Kilburn JO. Determination of in vitro susceptibility of Mycobacterium avium complex strains and Mycobacterium tuberculosis to a spiropiperidyl rifampicin. Am Rev Respir Dis 1982; 126: 586–7

    PubMed  CAS  Google Scholar 

  7. Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis 1985; 132: 710–1

    PubMed  CAS  Google Scholar 

  8. Delia Bruna C, Jabes D, Rossi R, et al. Mycobacterium tuberculosis (MTB): natural resistance and effect of prolonged exposure to rifabutin (RBT) and rifampicin (RMP) [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin: 1993; 1: 332

  9. Wynne B, Delia Bruna C, Imondi A, et al. M. avium complex (MAC); low frequency of natural resistance and absence of selection for resistant bacilli with rifabutin [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin: 1993; 1: 332

  10. Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177–82

    Article  PubMed  CAS  Google Scholar 

  11. Pretet S, Lebeaut A, Parrot R, et al. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J 1992; 5: 680–4

    PubMed  CAS  Google Scholar 

  12. Davis Jr CE, Carpenter JL, Trevino S, et al. In vitro susceptibility of Mycobacterium avium complex to antibacterial agents. Diag Microbiol Infect Dis 1987; 8: 149–55

    Article  CAS  Google Scholar 

  13. Cynamon MH. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob Agents Chemother 1985; 28: 440–1

    Article  PubMed  CAS  Google Scholar 

  14. Heifets LB, Iseman MD, Lindholm-Levy PJ, et al. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother 1985; 28: 570–5

    Article  PubMed  CAS  Google Scholar 

  15. Mascellino MT, Iona E, Fattorini L, et al. In vitro activity of clarithromycin alone or in combination with other antimicrobial agents against Mycobacterium avium-intracellulare: complex strains isolated from AIDS patients. J Chemother 1991; 3: 357–62

    PubMed  CAS  Google Scholar 

  16. Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutin: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988; 137: 719–21

    PubMed  CAS  Google Scholar 

  17. Yajko DM, Nassos PS, Hadley WK. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 117–20

    Article  PubMed  CAS  Google Scholar 

  18. Hawkins CC, Gold JW, Whimbey E, et al. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 184–8

    PubMed  CAS  Google Scholar 

  19. Perumal VK, Gangadharam PR, Iseman MD. Effect of rifabutin on the phagocytosis and intracellular growth of Mycobacterium intracellulare in mouse resident and activated peritoneal and alveolar macrophages. Am Rev Respir Dis 1987; 136: 334–7

    Article  PubMed  CAS  Google Scholar 

  20. Saito H, Sato K, Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle 1988; 69: 187–92

    Article  PubMed  CAS  Google Scholar 

  21. Yajko DM, Nassos PS, Sanders CA, et al. Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774. Am Rev Respir Dis 1989; 140: 1198–203

    Article  PubMed  CAS  Google Scholar 

  22. Perronne C, Gikas A, Truffot-Pernot C, et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 1990; 34: 1508–11

    Article  PubMed  CAS  Google Scholar 

  23. Gevaudan MJ, Bollet C, Mallet MN, et al. Intra-macrophagic activity of antibiotics combinations against Mycobacterium marinum [in French]. Pathol Biol 1991; 39: 436–41

    PubMed  CAS  Google Scholar 

  24. Ungheri D, Sanfilippo A. Activity of LM427 on Legionella spp: in vitro study and intracellular killing. In: Ishigami J, editor. Recent advances in chemotherapy — antimicrobial. Section 3. Tokyo: University of Tokyo Press, 1985: 919–20

    Google Scholar 

  25. Perumal VK, Gangadharam PR, Heifets LB, et al. Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on Mycobacterium intracellulare. Am Rev Respir 1985; 132: 1278–80

    CAS  Google Scholar 

  26. Ungheri D, Franceschi G, Delia Bruna C. Main human urinary metabolites of spiropiperidyl rifamycin LM 427: isolation and biological properties. In: Ishigami J, editor. Proceedings of the 14th International Congress of Chemotherapy; Tokyo: University of Tokyo Press, 1985; 3: 1917–8

    Google Scholar 

  27. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33: 1237–41

    Article  PubMed  CAS  Google Scholar 

  28. O’Brien RJ, Lyle MA, Snider Jr DE. Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987; 9: 519–30

    Article  PubMed  Google Scholar 

  29. Hoffner SE, Hjelm U, Kallenius G. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrob Agents Chemother 1993; 37: 1285–8

    Article  PubMed  CAS  Google Scholar 

  30. Hjelm U, Kaustova J, Kubin M, et al. Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid. Eur J Clin Microbiol Infect Dis 1992; 11: 51–4

    Article  PubMed  CAS  Google Scholar 

  31. Gevaudan MJ, Bollet C, Mallet MN, et al. Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi [in French]. Pathol Biol 1992; 40: 443–9

    PubMed  CAS  Google Scholar 

  32. Kent RJ, Bakhtiar M, Shanson DC. The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare. J Antimicrob Chemother 1992; 30: 643–50

    Article  PubMed  CAS  Google Scholar 

  33. Klemens SP, DeStefano MS, Cynamon MH. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992; 36: 2413–7

    Article  PubMed  CAS  Google Scholar 

  34. Ruf B, Schurmann D, Mauch H, et al. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. Infection 1992; 20: 267–72

    Article  PubMed  CAS  Google Scholar 

  35. Chiodini RJ. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis. J Antimicrob Chemother 1991; 27: 171–6

    Article  PubMed  CAS  Google Scholar 

  36. Klemens SP, Cynamon MH. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother 1991; 35: 2026–30

    Article  PubMed  CAS  Google Scholar 

  37. Dautzenberg B, Truffot C, Mignon A, et al. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d’Etude et de Traitement des Infections a Mycobacteries Resistantes. Tubercle 1991; 72: 168–75

    Article  PubMed  CAS  Google Scholar 

  38. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828–33

    Article  PubMed  CAS  Google Scholar 

  39. Schoenfelder J, Souder D, Smith J, et al. Rifabutin treatment for bacteremia due to Mycobacterium avium complex (MAC) in patients who received rifabutin or placebo in the MAC prevention studies 023 and 027 [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993: 1: 341

  40. Von Reyn CF, Brown ST, Arbeit RD. Rifabutin prophylaxis against Mycobacterium avium complex infection [letter]. N Engl J Med 1994; 330: 437

    Google Scholar 

  41. O’Brien RJ, Geiter LJ, Lyle MA. Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. Am Rev Respir Dis 1990; 141: 821–6

    PubMed  Google Scholar 

  42. Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992; 73: 33–8

    Article  PubMed  CAS  Google Scholar 

  43. Rastogi N, Ross BC, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1992; 11: 901–7

    Article  PubMed  CAS  Google Scholar 

  44. Mancini P, Pasqua F, Mazzei L, et al. Rifabutin treatment for tuberculosis patients with liver function abnormalities [letter]. J Antimicrob Chemother 1992; 30: 242

    Article  PubMed  CAS  Google Scholar 

  45. Gillespie SH, Baskerville AJ, Davidson RN, et al. The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection [letter]. J Antimicrob Chemother 1990; 25: 490–1

    Article  PubMed  CAS  Google Scholar 

  46. Zaugg M, Salfinger M, Opravil M, et al. Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin Infect Dis 1993; 16: 540–9

    Article  PubMed  CAS  Google Scholar 

  47. Nathan V, Mehta JB, Dralle W. Rifabutin in the treatment of cavitary lung disease due to Mycobacterium gordonae. South Med J 1993; 86: 839–41

    Article  PubMed  CAS  Google Scholar 

  48. Yoder LJ, Jacobson RR, Hastings RC. The activity of rifabutin against Mycobacterium leprae. Lepr Rev 1991; 62: 280–7

    PubMed  CAS  Google Scholar 

  49. Riva M, Crippa S, Di Palma F, et al. Disseminated tuberculosis of the central nervous system responsive to rifabutin. Ital J Neurol Sci 1990; 11: 163–9

    Article  PubMed  CAS  Google Scholar 

  50. Weiser B, Burger H, Eilbott DJ, et al. Efficacy of rifabutin in the treatment of AIDS-related complex. AIDS 1989; 3: 823–7

    Article  PubMed  CAS  Google Scholar 

  51. Torseth J, Bhatia G, Harkonen S, et al. Evaluation of the antiviral effect of rifabutin in AIDS-related complex. J Infect Dis 1989; 159: 1115–8

    Article  PubMed  CAS  Google Scholar 

  52. Mauch H, Reichert B, Ruf B, et al. Resistance testing of M. avium-intracellulare and M. tuberculosis of AIDS patients with new drugs and drug combinations [in German]. Pneumologie 1990; 44 Suppl 1: 504–6

    PubMed  Google Scholar 

  53. Yamamoto T, Amitani R, Kuze F, et al. In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex [in Japanese]. Kekkaku 1990; 65: 805–10

    PubMed  CAS  Google Scholar 

  54. Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 1992; 52: 335–41

    Article  PubMed  CAS  Google Scholar 

  55. Mandell GL, Sande MA. Drugs used in the chemotherapy of tuberculosis and leprosy. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1150

    Google Scholar 

  56. Rifabutin [editorial]. Med Let Drugs Ther 1993; 35: 36–8

  57. Strolin Benedetti M, Efthymiopoulos C, Sassella D, et al. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990; 20: 1113–9

    Article  PubMed  CAS  Google Scholar 

  58. Cocchiara G, Strolin Benedetti M, Vicario GP, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989; 19: 769–80

    Article  PubMed  CAS  Google Scholar 

  59. Vigevani A, Ballabio M, Gioia B, et al. Identification of urinary metabolites of rifamycin LM 427 in man. J Antibiot 1985; 38: 1799–802

    Article  PubMed  CAS  Google Scholar 

  60. Siegal FP, Eilbott D, Burger H, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990; 4: 433–41

    Article  PubMed  CAS  Google Scholar 

  61. Levin RH, Bolinger AM. Treatment of nontuberculous mycobacterial infections in pediatric patients. Clin Pharm 1988; 7: 545–51

    PubMed  CAS  Google Scholar 

  62. Lewis L, Jacobsen F, Mueller B, et al. A phase I/II assessment of oral rifabutin suspension for the prophylaxis of Mycobacterium avium complex in HIV-infected children [abstract]. Abstracts of the First National Conference on Human Retroviruses and Related Infections; 1993 Dec 12–16; Washington, DC, 1993: 107

  63. Oesch F, Arand M, Strolin Benedetti M, et al. Inducing properties of rifabutin and rifampicin for selected drug metabolizing enzymes in female rat liver [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 328

  64. Perucca E, Grimaldi R, Frigo GM, et al. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988; 34: 595–9

    Article  PubMed  CAS  Google Scholar 

  65. Breda M, Pianezzola E, Strolin Benedetti M, et al. A study of the effects of rifabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers. Drug Metabol Drug Interact 1992; 10: 323–40

    Article  PubMed  CAS  Google Scholar 

  66. Loos U, Musch E, Jensen JC, et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985; 63: 1205–11

    Article  PubMed  CAS  Google Scholar 

  67. Benedetti MS, Edwards DM, Pogessi I, et al. Pharmacokinetics of rifabutin in hepatic insufficiency [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 501

  68. Narang PK, Schoenfelder J, Bianchine JR. Impact of altered rifabutin disposition in renal disease on its safety in AIDS patients (CD4 < 200/µL). AIDS 1992; 6 (Suppl. 1): 90

    Google Scholar 

  69. Sale M, Narang PK. Population based assessment of rifabutin and alkaline phosphatase effect on zidovudine disposition in AIDS patients [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 505

  70. Sahai J, Foss N, Li R, et al. The effect of rifabutin (R) on didanosine (ddI) pharmacokinetics [abstract]. In: Abstracts of the First National Conference on Human Retroviruses and Related Infections; 1993 Dec 12–16; Washington, DC, 1993: 135

  71. Vandevelde C, Chang A, Andrews D, et al. Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991; 11: 88–9

    PubMed  CAS  Google Scholar 

  72. DATRI 001 Study Group. Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis: evidence for a drug interaction [abstract]. Abstracts of the First National Conference on Human Retroviruses and Related Infections; 1993 Dec 12–16; Washington, DC, 1993: 106

  73. Sawyer RC, Brown LS, Narang PK, et al. Evaluation of a possible pharmacologic interaction between rifabutin (RIF) and methadone (MET) in HIV (+) injecting drug users (IDUs) [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 501

  74. Trapnell CB, Narang PK, Li R, et al. Fluconazole (FLU) increases rifabutin (RIF) absorption in HIV (+) patients on stable zidovudine (ZDV) therapy [abstract]. In: Abstracts of the Ninth International Conference on AIDS; 1993 Jun 6–11; Berlin, 1993; 1: 504

  75. Narang PK, Trapnell CB, Schoenfelder JR, et al. Fluconazole and enhanced effect of rifabutin prophylaxis [letter]. N Engl J Med 1994; 18: 1316–7

    Article  Google Scholar 

  76. Fuller JD, Stanfield LED, Craven DE. Rifabutin prophylaxis and uveitis [letter]. N Engl J Med 1994; 330: 1315–6

    Article  PubMed  CAS  Google Scholar 

  77. Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis. Ann Int Med 1994; 121: 510–2

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas, 78284-6205, USA

    Michael H. Skinner

  2. Division of Clinical Pharmacology, Stanford University Medical Center, Stanford, California, USA

    Terrence F. Blaschke

Authors
  1. Michael H. Skinner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terrence F. Blaschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skinner, M.H., Blaschke, T.F. Clinical Pharmacokinetics of Rifabutin. Clin. Pharmacokinet. 28, 115–125 (1995). https://doi.org/10.2165/00003088-199528020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199528020-00003

Keywords

Search

Navigation